Bone and soft tissue sarcomas, tumors of the skinBone and soft tissue sarcomas, tumors of the skinСаркомы костей, мягких тканей и опухоли кожи2219-46142782-3687Publishing House ABV Press350SOFT TISSUE SARCOMASСАРКОМЫ МЯГКИХ ТКАНЕЙComparative study of clinical efficacy and safety of isolated limb perfusion with hyperthermia in patients with soft tissue sarcomasСравнительное изучение клинической эффективности и безопасности метода изолированной перфузии конечностей с гипертермией у больных с саркомами мягких тканейKharatishviliT. K.ХаратишвилиТ. К.
Russian Federation

Moscow

г. Москва

PetrochenkoN. S.ПетроченкоН. С.
Russian Federation

Moscow

г. Москва

petrochenko_nikolayy@rambler.ruBokhyanB. U.БохянБ. Ю.
Russian Federation

Moscow

г. Москва

N.N. Blokhin Russian Cancer Research Center Ministry of Health of the Russian FederationФГБУ «РОНЦ им. Н.Н. Блохина» Минздрава России201220168432391601202216012022Copyright ©; 2016, Kharatishvili T.K., Petrochenko N.S., Bokhyan B.U.Copyright ©; 2016, Харатишвили Т.К., Петроченко Н.С., Бохян Б.Ю.2016Kharatishvili T.K., Petrochenko N.S., Bokhyan B.U.Харатишвили Т.К., Петроченко Н.С., Бохян Б.Ю.https://creativecommons.org/licenses/by/4.0https://sarbon.abvpress.ru/jour/article/view/350

Background. To estimate the effectiveness of locally advanced soft tissue sarcomas of the extremities using an isolated perfusion chemotherapy in conditions of hyperthermia.Methods. We performed the treatment results analysis of 57 patients with extremity soft tissue sarcomas. Patients were divided into 2 groups: first – 21 patients who received treatment with an isolated limb regional perfusion (ILP), melphalan (10 mg/l for lower limbs, and 13 mg/L for upper limb); second (control group) – 36 patients were treated with conventional methods of mutilating surgery. During the ILP original methodology for monitoring of chemotherapy income levels in the systemic circulation was used.Results. Patients undergoing ILP with locally advanced soft tissue sarcomas of the limbs can achieve overall 2year survival rate of 90,5% comparing to 75% in the control group. Local toxicity in most cases did not exceed grade I and II under Wieberdink scale. Systemic grade I–II by CTC scale toxicity was observed in only few cases.Conclusion. ILP is a promising method for the treatment of soft tissue sarcomas, contributing to the reduction of the tumor and prevent recurrence of the disease, thus avoiding performing the amputation surgery.

Цель работы. Оценка эффективности лечения пациентов с местнораспространенными саркомами мягких тканей конечностей с помощью изолированной химиотерапевтической перфузии в условиях гипертермии.Материалы и методы. Выполнен анализ результатов лечения 57 больных саркомами мягких тканей конечностей, которые были разделены на 2 группы: основная – 21 больной, получивший лечение с применением изолированной регионарной перфузии (ИРП) мелфалана (в количестве 10 мг/л объема для нижней конечности и 13 мг/л объема для верхней конечности); группа сравнения – 36 пациентов, в лечении которых были использованы стандартные методы с выполнением калечащей операции. При ИРП использовали оригинальную методику мониторинга уровня поступления химиопрепарата в системный кровоток.Результаты. Метод изолированной регионарной перфузии у больных с местнораспространенной формой сарком мягких тканей конечностей позволяет достичь общей 2-летней выживаемости 90,5%, в группе сравнения значение показателя составило 75%. Локальная токсичность, связанная с ИРП, в большинстве случаев не превышала I и II степени по шкале Wieberdink. Системная токсичность I–II степени по шкале CTC отмечена в единичных случаях.Заключение. Метод ИРП конечности является перспективным методом лечения сарком мягких тканей, способствующим редукции опухоли и предупреждению рецидивов заболевания, что позволяет избежать выполнения ампутационного хирургического вмешательства.

soft tissue sarcomaisolated regional perfusionchemotherapysurvivaltoxicityсаркома мягких тканейизолированная регионарная перфузияхимиотерапиявыживаемостьтоксичность1. Алиев М.Д., Долгушин Б.И., Демидова Л.В., Харатишвили Т.К., Буйденок Ю.В., Наркевич Б.Я., Феденко А.А., Бохян Б.Ю. Опыт использования методики изолированной регионарной химиотерапевтической перфузии конечностей. Саркомы костей, мягких тканей и опухоли кожи. 2010, № 4, с. 46-54.Алиев М.Д., Долгушин Б.И., Демидова Л.В., Харатишвили Т.К., Буйденок Ю.В., Наркевич Б.Я., Феденко А.А., Бохян Б.Ю. Опыт использования методики изолированной регионарной химиотерапевтической перфузии конечностей. Саркомы костей, мягких тканей и опухоли кожи. 2010, № 4, с. 46-54.2. Borden E.C., Baker L.N., Bell R.S. et al. Soft Tissue Sarcomas of Adults. Clinical Cancer Research. 2003, v. 9, p. 1941-1956.Borden E.C., Baker L.N., Bell R.S. et al. Soft Tissue Sarcomas of Adults. Clinical Cancer Research. 2003, v. 9, p. 1941-1956.3. Deroose J.P., Eggermont A.M., van Geel A.N., Burger J.W., den Bakker M.A., de Wilt J.H., Verhoef C. Long-term results of tumor necrosis factor α and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J. Clin. Oncol. 2011, v. 29, p. 4036-4044.Deroose J.P., Eggermont A.M., van Geel A.N., Burger J.W., den Bakker M.A., de Wilt J.H., Verhoef C. Long-term results of tumor necrosis factor α and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J. Clin. Oncol. 2011, v. 29, p. 4036-4044.4. Gronchi A. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. Ann. Surg. 2010, v. 251 (3), p. 506-511.Gronchi A. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. Ann. Surg. 2010, v. 251 (3), p. 506-511.5. Weitz J., Antonescu C.R., Brennan M.F. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J. Clin. Oncol. 2003, v. 21, p. 2719-2725.Weitz J., Antonescu C.R., Brennan M.F. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J. Clin. Oncol. 2003, v. 21, p. 2719-2725.6. Cormier J.N., Pollock R.E. Soft tissue sarcomas. CA Cancer J. Clin. 2004, v. 54 (2), p. 94-109.Cormier J.N., Pollock R.E. Soft tissue sarcomas. CA Cancer J. Clin. 2004, v. 54 (2), p. 94-109.7. Stojadinovic A., Leung D.H., Allen P. et al. Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables. J. Clin. Oncol. 2002, v. 20 (21), p. 4344-4352.Stojadinovic A., Leung D.H., Allen P. et al. Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables. J. Clin. Oncol. 2002, v. 20 (21), p. 4344-4352.8. Williard W.C., Hajdu S.I., Casper E.S., Brennan M.F. Comparison amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann. Surg. 1992, v. 215 (3), p. 269-275.Williard W.C., Hajdu S.I., Casper E.S., Brennan M.F. Comparison amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann. Surg. 1992, v. 215 (3), p. 269-275.9. Deroose J.P., van Geel A.N., Burger J.W., Eggermont A.M., Verhoef C. Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients. J. Surg. Oncol. 2012, v. 105, p. 563-569.Deroose J.P., van Geel A.N., Burger J.W., Eggermont A.M., Verhoef C. Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients. J. Surg. Oncol. 2012, v. 105, p. 563-569.10. Deroose J.P., Burger J.W., van Geel A.N., den Bakker M.A., de Jong J.S., Eggermont A.M., Verhoef C. Radiotherapy for soft tissue sarcomas after isolated limb perfusion and surgical resection: essential for local control in all patients? Ann. Surg. Oncol. 2011, v. 18, p. 321-327.Deroose J.P., Burger J.W., van Geel A.N., den Bakker M.A., de Jong J.S., Eggermont A.M., Verhoef C. Radiotherapy for soft tissue sarcomas after isolated limb perfusion and surgical resection: essential for local control in all patients? Ann. Surg. Oncol. 2011, v. 18, p. 321-327.11. Grunhagen D.J., de Wilt J.H., Ten Hagen T.L., Eggermont A.M. Technology insight: utility of TNFα-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat. Clin. Pract. Oncol. 2006, v. 3, p. 94-103.Grunhagen D.J., de Wilt J.H., Ten Hagen T.L., Eggermont A.M. Technology insight: utility of TNFα-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat. Clin. Pract. Oncol. 2006, v. 3, p. 94-103.12. Grunhagen D.J., de Wilt J.H., Graveland W.J. et al. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb threatening soft tissue sarcoma. Cancer. 2006, v. 106 (8), p. 1776-1784.Grunhagen D.J., de Wilt J.H., Graveland W.J. et al. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb threatening soft tissue sarcoma. Cancer. 2006, v. 106 (8), p. 1776-1784.13. Casali P.G. Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas. Ann. Oncol. 2012, v. 23 (Suppl. 10), p. 167-169.Casali P.G. Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas. Ann. Oncol. 2012, v. 23 (Suppl. 10), p. 167-169.14. Eilber F.C., Rosen G., Eckardt J., Forscher C., Nelson S.D., Selch M. et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J. Clin. Oncol. 2001, v. 19, p. 3203-3209.Eilber F.C., Rosen G., Eckardt J., Forscher C., Nelson S.D., Selch M. et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J. Clin. Oncol. 2001, v. 19, p. 3203-3209.15. Schwindenhammer В., Podleska L.E., Kutritz1 A., Bauer S., Sien-Yi Sheu1, Taeger G. et al. The pathologic response of resected synovial sarcomas to hyperthermic isolated limb perfusion with melphalan and TNFα: a comparison with the whole group of resected soft tissue sarcomas. World J. Surg. Oncol. 2013, v. 11, p. 185.Schwindenhammer В., Podleska L.E., Kutritz1 A., Bauer S., Sien-Yi Sheu1, Taeger G. et al. The pathologic response of resected synovial sarcomas to hyperthermic isolated limb perfusion with melphalan and TNFα: a comparison with the whole group of resected soft tissue sarcomas. World J. Surg. Oncol. 2013, v. 11, p. 185.16. Thijssens K.M., van Ginkel R.J., Pras E. et al. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy. Ann. Surg. Oncol. 2006, v. 13 (4), p. 518-524.Thijssens K.M., van Ginkel R.J., Pras E. et al. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy. Ann. Surg. Oncol. 2006, v. 13 (4), p. 518-524.